Rituximab plus purine nucleoside analogs in the treatment of indolent lymphoid malignancies

American Journal of Cancer

Volumn 4, Issue 5, 2005, Pages 279-292

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ALLERGIC REACTION; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL COUNT; CHILL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOLYSIS; CYTOMEGALOVIRUS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HAIRY CELL LEUKEMIA; HERPES SIMPLEX; HUMAN; HYPOTENSION; HYPOXIA; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INFECTION RISK; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOMA; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; URTICARIA; VIRUS REACTIVATION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 27644467899     PISSN: 11756357     EISSN: 11756357     Source Type: Journal    
DOI: 10.2165/00024669-200504050-00001     Document Type: Review

References (100)

1. Kosmas C, Stamatopoulos K, Stavroyianni N, et al. Anti CD20 based therapy of B cell lymphoma: state of the art. Leukemia 2002; 16: 2004-15
2. Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004; 45: 205-19
3. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58: 79-88
4. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 2001; 12: Suppl. 2: 1-4
5. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45
6. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 2000; 95: 3900-8
7. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mA correlates with segregation into lipid rafts. Blood 2003; 101: 1045-52
8. Manches O, Lui G, Chapero L, et al. In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949-54
9. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644-52
10. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20 induced apoptosis of malignant human B-cells. Cancer Immunol Immunother 2000; 48: 673-83
11. Smolewski P, Szmigielska-Kaplon A, Cebula B, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005; 40: 87-100
12. Czuczman MS, Veaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 27: 4659-64
13. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23
14. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104: 2269-71
15. Robak T. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. Transfus Apheresis Sci 2005; 32: 33-44
16. Shanafelt TD, Madueme HL, Wolf RC, et al. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Evans syndrome. Mayo Clin Proc 2003; 78: 1340-6
17. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004; 72: 79-88
18. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1015-27
19. Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 2004; 28, 5: 429-42
20. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1991; 340: 952-6
21. Dillman RO. Pentostatin (nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. Expert Rev Anticancer Ther 2004; 4: 27-36
22. Pettit AR. Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br J Haematol 2003; 121: 692-702
23. Genini D, Adachi S, Chao O, et al. Deoxyadenosine analogs induced programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-43
24. Marzo I, Perez-Galan P, Rubio-Felix D, et al. Cladribine induces apoptosis in human leukemia cells by caspase dependent and independent pathways acting on mitochondria. Biochem J 2001; 359: 537-46
25. Adkins JC, Peters DH, Markham A. Fludarabine: an update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-37
26. Robak T. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland. Ann Hematol 2005; 84: 63-70
27. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463-74
28. Zinzani PL. Non-Hodgkin's lymphoma: the evolving role of purine analogues. Best Pract Res Clin Haematol 2002; 15: 505-16
29. Johnson SA, Oscier DG, Leblond V. Waldenstrom's macroglobulinaemia. Blood Rev 2002; 16: 175-84
30. Evens AM, Gartenhaus RB. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2004; 5: 289-303
31. Grever MR. Pentostatin in the treatment of hairy cell leukemia. Best Pract Clin Haematol 2003; 16: 91-9
32. Goodman GR, Beutler E, Saven A. Cladribine in the treatment of hairy cell leukaemia. Best Pract Res Clin Haematol 2003; 16: 101-16
33. Begleiter A, Verburg L, Ashique A, et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-B-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875-81
34. Koski T, Vilpo L, Vilpo J. Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-B-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia. Leuk Res 1999; 23: 277-9
35. Tondini C, Balzarotti M, Ramoinelli I, et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Ann Oncol 2000; 11: 231-3
36. Karlsson K, Stromberg M, Jonsson V. Cladribine (CdA) or fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia: first interim analysis of data from the international randomized phase III trial [abstract no. 3470]. Blood 2004; 104 Suppl. 1: 945a
37. Robak T, Bloński JZ, Góra-Tybor J, et al. Cladribine with cyclophosphamide vs fludarabine with cyclophosphamide as first-line treatment in chronic lymphocytic leukemia: an early report of prospective randomized study (PALG CLL3) [abstract no. 364]. Hematologica 2005; 90 Suppl. 2: 143-4
38. Spiers AS, Moore D, Cassileth PA, et al. Remissions in hairy cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 1987; 316: 825-30
39. Weiss MA, Maslak PG, Juric JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukaemia. J Clin Oncol 2003; 21: 1278-84
40. Dilman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 433-8
41. Dearden C, Catovsky D. Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 1990; 62: 4-5
42. Morabito F, Stelitano C, Callea I, et al. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81: 224-31
43. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyade-nosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056-61
44. Byrd JC, Peterson B, Piro L, et al. A phase II study of cladribine treatment for fludarabine refractory B-cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 2003; 17: 323-7
45. O'Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330: 319-22
46. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia: updated results of the multicenter study of 378 patients. Br J Haematol 2000; 108: 357-68
47. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-86
48. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 2002; 87: 33-43
49. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxyline and rituximab. Anticancer Res 2000; 20: 2961-6
50. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-9
51. Rummel MJ, Chow KU, Hoelzer D, et al. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 2002; 29 (4 Suppl. 13): 12-4
52. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002; 100: 1765-73
53. Shan D, Gopal AK, Press OW. Synergistic effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Clin Cancer Res 2001; 7: 2490-5
54. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001; 7: 709-23
55. Smolewski P, Szmigielska A, Cebula B, et al. Pro-apoptotic effect of rituximab alone and in combination with purine nucleoside analogues in B-cell chronic lymphocytic leukemia cells measured by fluorochrome labeled inhibitors of caspase (FIICA) assay [abstract no. 1503]. Blood 2002; 100 Suppl. 1: 387a
56. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-20
57. Savage DG, Cohen NS, Hesdorffer CS, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 477-81
58. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent vs. sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALG B9712). Blood 2003; 101: 6-14
59. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-88
60. Wierda W, Faderl S, O'Brien S, et al. Combined cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) is active for relapsed and refractory patients with CLL [abstract no. 340]. Blood 2004; 104: 101a
61. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-8
62. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694-704
63. Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654-61
64. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-71
65. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALG 9011. Blood 2005; 105: 49-53
66. Hainsworth JD, Lithy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088-95
67. Cohen BJ, Moskowitz C, Straus D, et al. Cyclophosphamide, fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001; 42: 1015-22
68. Thomas DW, Owen RG, Johnson SA, et al. Superior quality and duration of responses among patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005; 46: 549-52
69. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-84
70. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-75
71. Damaj G, Lefrere F, Delarue R, et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003; 17: 1914-5
72. Robak T, Smolewski P, Urbańska-Ryś H, et al. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malig-nancies. Leuk Lymphoma 2004; 45: 937-44
73. Tsiara SN, Kapsalii HD, Chaidos A, et al. Treatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximab. Acta Haematol 2004; 111: 185-8
74. Drapkin R, Di Bella NJ, Faragher DC, et al. Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen. Clin Lymphoma 2003; 4: 169-75
75. Di Bella N, Reynolds C, Faragher D, et al. An open-label pilot study of pentostatin, mitoxantrone and rituximab in patients with previously untreated stage III or IV, low-grade non-Hodgkin lymphoma. Cancer 2005; 103: 978-84
76. Kay E, Geyer SM, Lin T, et al. Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia [abstract no. 339]. Blood 2004; 104: 100a
77. Robak T, Bloński JZ, Góra-Tybor J, et al. Cladribine alone or in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia: an early report of prospective randomized study [abstract no. 337]. Blood 2004; 104: 100a
78. Drapkin R. Pentostatin and rituximab in the treatment of patients with B-cell malignancies. Oncology (Huntingt) 2000; 14 (6 Suppl. 2): 25-9
79. Ogura M, Morishima Y, Kobayashi Y, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol 2004; 80: 267-77
80. Robak T, Blasinska-Morawiec M, Blonski J, et al. 2 - Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-Year experience in Poland. Eur J Haematol 1999; 62: 49-56
81. Bergman L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4: 371-5
82. Semour JF, Kurzrock R, Freireich EJ, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906-11
83. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559-66
84. Cheson BD. Infections and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-48
85. Van den Neste E, Delannoy A, Vandercam B, et al. Infections complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996; 56: 235-40
86. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723-9
87. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-7
88. McLaughlin P, Grillo-Lopez AL, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33
89. Tam CS, Seymour JF, Brown M, et al. Early and late infections consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica 2005; 90: 700-2
90. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxan-trone and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005; 105: 4573-5
91. Morrison VA, Rai KR, Peterson BL, et al. Therapy related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an Intergroup Study. J Clin Oncol 2003; 20: 3878-84
92. Robak T, Bloński JZ, Góra-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia treated with cladribine. Eur J Cancer 2004; 40: 383-9
93. Van Bessien K. Autologous and allogenic stem cell transplantation in follicular lymphoma. Transfus Apheresis Sci 2005; 32: 45-54
94. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression free survival in follicular lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 267-74
95. Khouri IF, Champlin RE. Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 2004; 31: 22-6
96. Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628-32
97. Lemieux B, Tartas S, Traulle C, et al. Rituximab related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 921-3
98. Tournilhac O, Cazin B, Lepretre S, et al. Impact of front line fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363-5
99. Lysak D, Koza V, Steinerova K, et al. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol 2005; 84: 456-61
100. Brugger W, Hirsch J, Grunebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004; 15: 1691-8